Livzon Pharmaceutical Group (HK:1513) has released an update.
Livzon Pharmaceutical Group Inc. has released its unaudited interim results for the first half of 2024, which are now available on the company’s and HKEx’s websites. This announcement follows the disclosure rules of The Stock Exchange of Hong Kong Limited and the full 2024 Interim Report will be accessible online and sent to H share holders opting for printed copies.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.
